Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Intrinsic Value
Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese herbal medicine and bio pharmaceutical products. [ Read More ]
The intrinsic value of one
Guizhou Xinbang Pharmaceutical Co Ltd
stock under the Base Case scenario is
6.56
CNY.
Compared to the current market price of 3.78 CNY,
Guizhou Xinbang Pharmaceutical Co Ltd
is
Undervalued by 42%.
Guizhou Xinbang Pharmaceutical Co Ltd's market capitalization is 7.3B CNY.
Guizhou Xinbang Pharmaceutical Co Ltd stock price is 3.78 CNY.
Guizhou Xinbang Pharmaceutical Co Ltd stock price (3.78 CNY) is 42% less than its Intrinsic Value (6.56 CNY).
Guizhou Xinbang Pharmaceutical Co Ltd stock price (3.78 CNY) is 17% less than its DCF Value (4.55 CNY). Open DCF Valuation
Guizhou Xinbang Pharmaceutical Co Ltd stock price (3.78 CNY) is 56% less than its Relative Value (8.57 CNY). Open Relative Valuation
Guizhou Xinbang Pharmaceutical Co Ltd has upside potential of 95% compared to the average analyst price target.
Open Wall St Estimates
Guizhou Xinbang Pharmaceutical Co Ltd's Revenue has grown by 1% over the past 12 months.
Guizhou Xinbang Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 5% to 3%.
Guizhou Xinbang Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 6% to 4%.
Guizhou Xinbang Pharmaceutical Co Ltd's Revenue has been growing by 3% per year for the last 3 years.
Guizhou Xinbang Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Guizhou Xinbang Pharmaceutical Co Ltd has positive Net Debt. This means that the company has more debt (1B CNY) than cash and short-term investments (1B CNY).
Guizhou Xinbang Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 4%.
Guizhou Xinbang Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is very low and is equal to 3%.
Guizhou Xinbang Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
Guizhou Xinbang Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Guizhou Xinbang Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Guizhou Xinbang Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Guizhou Xinbang Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
Guizhou Xinbang Pharmaceutical Co Ltd has a very low three-year average ROE (Return on Equity): 4%. The company is not efficient at transforming stockholders' equity into net income.
Guizhou Xinbang Pharmaceutical Co Ltd's short-term assets (6B CNY) exceed its short-term liabilties (2B CNY).
Guizhou Xinbang Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 3.35.
Guizhou Xinbang Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.2.
Guizhou Xinbang Pharmaceutical Co Ltd's long-term assets (10B CNY) exceed its long-term liabilties (3B CNY).
Valuation Backtest
Guizhou Xinbang Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Guizhou Xinbang Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Guizhou Xinbang Pharmaceutical Co Ltd
Balance Sheet Decomposition
Guizhou Xinbang Pharmaceutical Co Ltd
| Current Assets | 5.8B |
| Cash & Short-Term Investments | 1.1B |
| Receivables | 3.5B |
| Other Current Assets | 1.3B |
| Non-Current Assets | 3.8B |
| Long-Term Investments | 343.8m |
| PP&E | 2.6B |
| Intangibles | 786.7m |
| Other Non-Current Assets | 151.4m |
| Current Liabilities | 2.4B |
| Accounts Payable | 674.7m |
| Accrued Liabilities | 13.9m |
| Short-Term Debt | 1.4B |
| Other Current Liabilities | 394m |
| Non-Current Liabilities | 319.5m |
| Long-Term Debt | 20.1m |
| Other Non-Current Liabilities | 299.4m |
Earnings Waterfall
Guizhou Xinbang Pharmaceutical Co Ltd
|
Revenue
|
6.5B
CNY
|
|
Cost of Revenue
|
-5.3B
CNY
|
|
Gross Profit
|
1.2B
CNY
|
|
Operating Expenses
|
-834.1m
CNY
|
|
Operating Income
|
370m
CNY
|
|
Other Expenses
|
-140m
CNY
|
|
Net Income
|
230m
CNY
|
Free Cash Flow Analysis
Guizhou Xinbang Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Guizhou Xinbang Pharmaceutical Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Guizhou Xinbang Pharmaceutical Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Guizhou Xinbang Pharmaceutical Co Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Guizhou Xinbang Pharmaceutical Co Ltd's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Guizhou Xinbang Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Guizhou Xinbang Pharmaceutical Co Ltd
is 7.37 CNY
.
Shareholder Return
Price
Guizhou Xinbang Pharmaceutical Co Ltd
| Average Annual Return | -1.58% |
| Standard Deviation of Annual Returns | 40.19% |
| Max Drawdown | -71% |
| Market Capitalization | 7.3B CNY |
| Shares Outstanding | 1 943 849 984 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Guizhou Xinbang Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese herbal medicine and bio pharmaceutical products. The company is headquartered in Guiyang, Guizhou and currently employs 5,796 full-time employees. The company went IPO on 2010-04-16. The firm operates its businesses through three segments. The Pharmaceutical Manufacturing segment is engaged in the manufacture and distribution of Chinese patent medicines, such as Ginkgo Leaves Tablets. The Pharmaceutical Distribution segment includes rapid wholesale business and medicine retail business. The Medical Services segment is engaged in the provision of medical services. The company operates its businesses primarily in domestic markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Guizhou Xinbang Pharmaceutical Co Ltd
stock under the Base Case scenario is
6.56
CNY.
Compared to the current market price of 3.78 CNY,
Guizhou Xinbang Pharmaceutical Co Ltd
is
Undervalued by 42%.
You don't have any saved screeners yet
